Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B, Biomarker-Guided Trial to Evaluate ALRN-6924 in Combination with IBRANCE (Palbociclib) in MDM2-Amplified Solid Tumors

Trial Profile

A Phase 1B, Biomarker-Guided Trial to Evaluate ALRN-6924 in Combination with IBRANCE (Palbociclib) in MDM2-Amplified Solid Tumors

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2018

At a glance

  • Drugs ALRN 6924 (Primary) ; Palbociclib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Aileron Therapeutics
  • Most Recent Events

    • 09 Dec 2018 New trial record
    • 27 Nov 2018 According to an Aileron Therapeutics media release, Aileron expects this trial to start enrolling patients with solid tumors in the first quarter of 2019.
    • 27 Nov 2018 According to an Aileron Therapeutics media release, the company has entered into a clinical trial collaboration with Pfizer to evaluate the combination of ALRN-6924 and Palbociclib in MDM2-amplified cancers.Pfizer will provide drug supply in support of the trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top